Table: Santen Pharm -2022/23 group results (IFRS)
11/05/2023 07:00
May 11 (Reuters)-
Santen Pharmaceutical Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
Year ended Year ended Year to NEXT
Mar 31, 2023 Mar 31, 2022 Mar 31, 2024 YEAR
LATEST YEAR-AGO COMPANY COMPANY
RESULTS RESULT FORECAST H1 FORECAST
Sales 279.04 266.26 273.00
(+4.8 pct) (+6.7 pct) (-2.2 pct)
Operating loss 3.09 35.89 32.00
(+194.5 pct)
Pretax loss 5.80 35.62 29.80
(+204.7 pct)
Net loss 14.95 27.22
(+192.3 pct)
EPS Basic loss 38.60 yen 68.07 yen 61.24 yen
EPS Diluted loss 38.60 yen 67.97 yen
Ann Div 32.00 yen 32.00 yen 32.00 yen
-Q2 Div 16.00 yen 16.00 yen 16.00 yen
-Q4 Div 16.00 yen 16.00 yen 16.00 yen
NOTE - Santen Pharmaceutical Co Ltd.
(Figures are reported based on international accounting rules (IFRS).)
If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half
dividend and Q4 to the second-half dividend announced before a new corporate law in
2006 allowed companies to pay and report dividends on a quarterly basis.
*Net - represents Net profit attributable to owners of the parent company.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4536.T